Navigation Links
Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial
Date:4/27/2009

ced breast cancer and a Phase II combination therapy trial for the treatment of non-small cell lung cancer. A Phase I bavituximab monotherapy trial in advanced solid cancers is also continuing.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and hepatitis C virus infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the rate of objective tumor response for the expansion stage of this trial will not be consistent with the objective tumor response experienced in the first stage of the trial and the risk that the standard carboplatin and paclitaxel response rate will not be improved as a result of the combination therapy. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could c
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Peregrine Pharmaceuticals Awarded New U.S. Patent Further Strengthening Its Anti-Phospholipid Patent Portfolio
2. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
3. Peregrine Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
4. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
5. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
6. Peregrine Pharmaceuticals Mourns Loss of Chairman Thomas A. Waltz
7. Peregrine Pharmaceuticals Enters Into a Loan Agreement for up to $10 Million
8. Peregrine Pharmaceuticals to Report Second Quarter FY 2009 Financial Results
9. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
10. Peregrine Pharmaceuticals to Present at BIO Investor Forum 2008
11. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... 2015 Neogen Corporation (NASDAQ: NEOG ) ... quarter of fiscal 2015, which ended Feb. 28, increased ... $6,575,000. Earnings per share in the current quarter were ... net income increased 17% over prior year to $24,142,000, ... per share, for the same period a year ago. ...
(Date:3/26/2015)... (PRWEB) March 26, 2015 Ale Gicqueau, ... Chen, Director of Clinical Affairs at Align Technology, on ... at the upcoming ACRP 2015 Global Conference and Exhibition ... City, Utah. , During the poster presentation, Ale ... creating and running a Postmarket Registry, the requirements and ...
(Date:3/25/2015)... , March 25, 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" ... as a result of recent discussions with certain shareholders ... of the Company, after dealing with certain matters including ... meeting of shareholders on March 26, 2015 (the "Meeting") ... election of directors will take place when the Meeting ...
(Date:3/25/2015)... 25, 2015 Laboratory workers can ... and Analytical Balances to get best-performing features while ... weighing balances from the trusted brand include: , ... increase your efficiency by providing a large weighing ... Weighing modes include parts counting, percent weighing, checkweighing, ...
Breaking Biology Technology:Neogen reports 13% increase in net income 2Neogen reports 13% increase in net income 3Neogen reports 13% increase in net income 4Neogen reports 13% increase in net income 5Neogen reports 13% increase in net income 6Neogen reports 13% increase in net income 7Neogen reports 13% increase in net income 8Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 2Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 3SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 2SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 3SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 4SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 5New Economical Top-Loading and Analytical Symmetry Balances from Cole-Parmer 2
... Dec. 5 Representatives from over 40,Shanghai ... attendance, took,part in the first annual Cinpathogen ... hosted by Cinpathogen Inc. and chaired by,Professor ... Epidemiology,Institute, covered current developments in clinical laboratory ...
... ( http://www.CMELLC.com ),a leading provider of fully accredited ... new structure and management team,put in place to ... address the educational needs of healthcare professionals moving,forward., ... role of senior vice,president and general manager, and ...
... $8.1 Million Financing in Connection ... Reverse Stock Split Planned for January 2008, ... today announced that the Company has:, - Signed an agreement ... based in Israel. The acquisition,is expected to close tomorrow. The initial ...
Cached Biology Technology:Cinpathogen Brings Together Over 40 Shanghai Area Hospitals at the First Annual Cinpathogen Hematology Conference 2CME LLC Restructures, Announces Its New Executive Management Team 2Amarin Signs Agreement to Acquire Ester Neurosciences 2Amarin Signs Agreement to Acquire Ester Neurosciences 3Amarin Signs Agreement to Acquire Ester Neurosciences 4Amarin Signs Agreement to Acquire Ester Neurosciences 5Amarin Signs Agreement to Acquire Ester Neurosciences 6Amarin Signs Agreement to Acquire Ester Neurosciences 7Amarin Signs Agreement to Acquire Ester Neurosciences 8Amarin Signs Agreement to Acquire Ester Neurosciences 9Amarin Signs Agreement to Acquire Ester Neurosciences 10Amarin Signs Agreement to Acquire Ester Neurosciences 11
(Date:3/12/2015)... 2015 IriTech, a leading iris based identity ... Texas Instruments Design Network, announced today that the Chief ... IriShield USB MK2120U device during a launching event of ... The iris scanner is manufactured by ... India through its Indian partner, ...
(Date:3/11/2015)... , March 11, 2015   The ... its platform to scientifically measure and harness music ... to real-time biometrics and objective measurements of physiology, ... music at scale in large populations. It is ... technologists and clinicians perform rigorous studies and accelerate ...
(Date:3/5/2015)... 2015 In Brazil , cloud ... using these solutions and 42 percent planning to invest in ... 25 percent of the companies will be investing in these ... of companies in the region are currently opting for the ... will command significant attention in the coming years. This trend ...
Breaking Biology News(10 mins):Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 3Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 4
... ROCKVILLE, Maryland July 9, 2009 Human ... the New England Journal of Medicine of ... showed the life-saving potential of the Company,s human monoclonal ... of human safety studies, which supported the use of ...
... appearing in Environmental Health Perspectives (EHP) ... for the Project on Emerging Nanotechnologies (PEN), focuses ... It provides an overview of current practices; ... safety implications; and possible future directions for nanoremediation. ...
... Van Andel Research Institute (VARI) investigators have ... target in the treatment of the most aggressive forms ... few treatment options. "Breast cancer mortality rates are ... traditional treatments tend to be more aggressive and have ...
Cached Biology News:Data published in the New England Journal of Medicine support use of raxibacumab (ABthrax) for the treatment of inhalation anthrax 2Contaminated site remediation: Are nanomaterials the answer? 2Possible drug target found for one of the most aggressive breast cancers 2
...
PURA Immunogen: PURA (NP_005850, 183 a.a. ~ 293 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Mouse monoclonal [3F8 ] to smooth muscle Myosin heavy chain I ( Abpromise for all tested applications). entrezGeneID: 4629 SwissProtID: P35749...
Phospho-CD18 (Ser756/Thr758/759) Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Biology Products: